Literature DB >> 33250455

Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes　- A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society.

Eiichi Araki1, Atsushi Tanaka2, Nobuya Inagaki3, Hiroshi Ito4, Kohjiro Ueki5, Toyoaki Murohara6, Kenjiro Imai7, Masataka Sata8, Takehiro Sugiyama7, Hideki Ishii9, Shunsuke Yamane3, Takashi Kadowaki10, Issei Komuro11, Koichi Node2.   

Abstract

Entities:  

Keywords:  Cardiovascular disease; Consensus Statements; Diabetes

Mesh：

Year:  2020        PMID： 33250455     DOI： 10.1253/circj.CJ-20-0865

Source DB:  PubMed          Journal:  Circ J        ISSN： 1346-9843            Impact factor:   2.993


× No keyword cloud information.
  4 in total

1.  Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.

Authors:  Atsunori Kashiwagi; Shingo Shoji; Satoshi Onozawa; Yoshinori Kosakai; Miina Waratani; Yuichiro Ito
Journal:  J Diabetes Investig       Date:  2022-04-09       Impact factor: 3.681

2.  Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Authors:  Takashi Kadowaki; Nobuya Inagaki; Hirotaka Watada; Kazuyo Sasaki; Kazumi Mori-Anai; Tomohisa Iwasaki; Tatsuki Teranishi
Journal:  Adv Ther       Date:  2022-02-09       Impact factor: 3.845

Review 3.  Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?

Authors:  Hideki Ishii
Journal:  J Diabetes Investig       Date:  2022-04-18       Impact factor: 3.681

4.  Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Hiroki Teragawa; Yosuke Okada; Toshinari Takamura; Isao Taguchi; Shigeru Toyoda; Hirofumi Tomiyama; Shinichiro Ueda; Yukihito Higashi; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2021-07-31       Impact factor: 9.951
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.